Werewolf Therapeutics’ (HOWL) Market Outperform Rating Reiterated at JMP Securities

JMP Securities reiterated their market outperform rating on shares of Werewolf Therapeutics (NASDAQ:HOWL) in a research note issued to investors on Monday morning, Benzinga reports. JMP Securities currently has a $12.00 target price on the stock.

Separately, HC Wainwright restated a buy rating and issued a $15.00 price target on shares of Werewolf Therapeutics in a report on Monday.

Werewolf Therapeutics Trading Down 4.2 %

HOWL opened at $5.48 on Monday. The firm has a market capitalization of $237.56 million, a price-to-earnings ratio of -5.03 and a beta of 0.71. The company’s 50 day moving average price is $6.12 and its two-hundred day moving average price is $4.73. The company has a debt-to-equity ratio of 0.29, a current ratio of 7.14 and a quick ratio of 7.14. Werewolf Therapeutics has a fifty-two week low of $1.57 and a fifty-two week high of $8.19.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its quarterly earnings results on Thursday, March 7th. The company reported ($0.33) EPS for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.10. Werewolf Therapeutics had a negative net margin of 256.33% and a negative return on equity of 36.43%. The business had revenue of $1.50 million for the quarter, compared to analysts’ expectations of $2.75 million. As a group, research analysts predict that Werewolf Therapeutics will post -1.38 earnings per share for the current year.

Institutional Trading of Werewolf Therapeutics

Several hedge funds have recently bought and sold shares of the business. PFM Health Sciences LP grew its holdings in shares of Werewolf Therapeutics by 35.6% during the fourth quarter. PFM Health Sciences LP now owns 3,468,177 shares of the company’s stock valued at $13,387,000 after buying an additional 909,895 shares during the last quarter. Denali Advisors LLC bought a new stake in Werewolf Therapeutics during the 1st quarter worth approximately $172,000. Lighthouse Investment Partners LLC purchased a new stake in shares of Werewolf Therapeutics in the fourth quarter worth approximately $87,000. Certuity LLC bought a new position in shares of Werewolf Therapeutics in the fourth quarter valued at approximately $39,000. Finally, Financial Perspectives Inc lifted its holdings in shares of Werewolf Therapeutics by 80.0% in the fourth quarter. Financial Perspectives Inc now owns 6,750 shares of the company’s stock valued at $26,000 after purchasing an additional 3,000 shares in the last quarter. Institutional investors and hedge funds own 64.84% of the company’s stock.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.